Parkinson DiseaseNCT07843667
Pulmonary and Musculoskeletal Impairments in Parkinson's Patients
An observational study of Parkinson Disease, run by Izmir Democracy University at 1 site in Turkey (Türkiye).
Trial summary
In this study, the relationships between pain severity, chest mobility, cough strength, muscle strength, physical activity levels, and quality of life in Parkinson's disease patients will be investigated. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Parkinson Disease
- What is being tested?
- Physical Evaluations of Individuals with Parkinson's Disease
- How many people
- 30 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 13 May 2023to 30 Dec 2024
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: At least 30 Parkinson's patients will be included in the analyses.
Who may be able to join
- Being over 18 years old,
- Volunteering to participate in the research,
- Being diagnosed with Parkinson's disease
- Comorbid conditions (such as hypertension, diabetes) are under control
- Being able to perceive assessments (Standardized Mini Mental Test score of 24 and above)
- Having the ability to ambulate and walk independently
- Being in stage 1 - 4 according to the Modified Hoehn-Yahr Scale
Who cannot join
- Sudden drug or dose change during the study period
- A history of any acute/chronic orthopedic, cardiovascular, pulmonary, psychiatric or neuromuscular disease that may prevent measurements from being made.
- Having had myocardial infarction and pulmonary embolism in the last 30 days,
- Having a history of additional neurological (stroke, head trauma, peripheral nerve diseases, brain and spinal cord tumors, etc.) diseases other than Parkinson's disease
- Having severe vision loss or vestibular dysfunction
- Patients with blood pressure values above 140/90 and below 90/50 in blood pressure measurements made before the study, with arrhythmia on ECG, with a history of shortness of breath and/or palpitation
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Investigation of Chest Mobility, Cough Strength, Muscle Strength, Physical Activity and Quality of Life in Parkinson's Patients
In this study, the relationships between pain severity, chest mobility, cough strength, muscle strength, physical activity levels, and quality of life in Parkinson's disease patients will be investigated.
Read the detailed description
In patients with Parkinson's disease, motor and non-motor symptoms can vary depending on physical inactivity, the nature of the disease, and its treatment. The relationships between pain, chest wall immobility, cough strength, muscle strength, physical activity levels, and quality of life in Parkinson's patients have not yet been fully elucidated in the literature. Therefore, this study aims to shed light on this subject.
- Conditions
- Parkinson Disease
- Being tested
- Physical Evaluations of Individuals with Parkinson's Disease
- Keywords
- pain, chest mobility, muscle strength, physical activity, quality of life
- Medical subject headings
- Parkinson Disease, Pain, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Physical Evaluations of Individuals with Parkinson's DiseaseOther
In this study, data regarding chest mobility, cough strength, muscle strength, physical activity, and quality of life-collected from Parkinson's patients via face-to-face interviews-will be analyzed.
The data for all these assessments were collected in a single session lasting a maximum of approximately one hour. Step counts for each individual were tracked using a pedometer over a period of three days.
| Study group | Role | What they receive |
|---|---|---|
| Parkinson's disease group | This group will consist of individuals with Parkinson disease. Receives: Other: Physical Evaluations of Individuals with Parkinson's Disease |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total quality of life score evaluated by Parkinson's Disease Questionnaire (PDQ-39) questionnaire.
The status of quality of life was evaluated using Parkinson's Disease Questionnaire (PDQ-39) questionnaire. Parkinson's Disease Questionnaire-39 (PDQ39) is a 39-item quality of life questionnaire. Evaluation for each question item ranges from 0 (no problem) to 4 (constant problem). Low scores in total indicate an improvement in people's quality of life.
Measured: through study completion, an average of 1 year
Secondary outcomes (5)
Cough Strength
Cough Strength was evaluated using a Peak Flow Meter.
Measured: through study completion, an average of 1 year
Daily average step count
Daily average step counts were recorded via a pedometer everyday within 3 days after confirming enrolment. All individuals will be asked to carry their pedometers with them during the day and record to their diaries.
Measured: through study completion, an average of 1 year
Hand grip strength
Hand grip strength was evaluated using a hand dynamometer.
Measured: through study completion, an average of 1 year
Chest mobility
Chest mobility was evaluated using a tape measure.
Measured: through study completion, an average of 1 year
Cognitive status
Cognitive state will be evaluated using The mini-mental state examination (MMSE). It is an 11 question test. The highest score from the test is 30 points. Scores of 23 and lower indicate cognitive dysfunction, and scores of 24 and higher indicate normal cognitive level.
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Sep 2026
- Study start13 May 2023
- Primary completion30 Aug 2024
- Study completion30 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 30 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Izmir Democracy University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gulsah Bargi, Izmir Democracy University
- Investigators
- GÜLŞAH BARĞI, Assoc Prof, Study director, Izmir Democracy UniversityMERVE ŞAHİN, Principal investigator, Izmir Democracy UniversityÖZLEM ÇİNAR ÖZDEMİR, Principal investigator, Abant Izzet Baysal UniversityYASEMİN ÜNAL, Principal investigator, Bandirma Health Practice and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07843667
- Sponsor's protocol ID
- Impairments in Parkinson
- Status last verified
- Sep 2026
- First submitted
- 21 Sep 2026
- Last updated
- 28 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Shalash A, Roushdy T, Essam M, Fathy M, Dawood NL, Abushady EM, Elrassas H, Helmi A, Hamid E. Mental Health, Physical Activity, and Quality of Life in Parkinson's Disease During COVID-19 Pandemic. Mov Disord. 2020 Jul;35(7):1097-1099. doi: 10.1002/mds.28134. Epub 2020 Jun 7. No abstract available.
PubMed 32428342
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of Chest Mobility, Cough Strength, Muscle Strength, Physical Activity and Quality of Life in Parkinson's Patients
- ClinicalTrials.gov ID
- NCT07843667
- Acronym / sponsor ID
- Impairments in Parkinson
- Conditions
- Parkinson Disease
- Keywords
- pain, chest mobility, muscle strength, physical activity, quality of life
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Izmir Democracy UniversityUniversity, hospital or other
- Study start
- 13 May 2023 (actual)
- Primary completion
- 30 Aug 2024 (actual)
- Study completion
- 30 Dec 2024 (actual)
- First posted
- 28 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this study, the relationships between pain severity, chest mobility, cough strength, muscle strength, physical activity levels, and quality of life in Parkinson's disease patients will be investigated.
Detailed description
In patients with Parkinson's disease, motor and non-motor symptoms can vary depending on physical inactivity, the nature of the disease, and its treatment. The relationships between pain, chest wall immobility, cough strength, muscle strength, physical activity levels, and quality of life in Parkinson's patients have not yet been fully elucidated in the literature. Therefore, this study aims to shed light on this subject.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Parkinson's disease group | – | Other: Physical Evaluations of Individuals with Parkinson's DiseaseThis group will consist of individuals with Parkinson disease. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- At least 30 Parkinson's patients will be included in the analyses.
Key inclusion criteria (7 listed)
- Being over 18 years old,
- Volunteering to participate in the research,
- Being diagnosed with Parkinson's disease
- Comorbid conditions (such as hypertension, diabetes) are under control
- Being able to perceive assessments (Standardized Mini Mental Test score of 24 and above)
Key exclusion criteria (6 listed)
- Sudden drug or dose change during the study period
- A history of any acute/chronic orthopedic, cardiovascular, pulmonary, psychiatric or neuromuscular disease that may prevent measurements from being made.
- Having had myocardial infarction and pulmonary embolism in the last 30 days,
- Having a history of additional neurological (stroke, head trauma, peripheral nerve diseases, brain and spinal cord tumors, etc.) diseases other than Parkinson's disease
- Having severe vision loss or vestibular dysfunction
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Physical Evaluations of Individuals with Parkinson's DiseaseIn this study, data regarding chest mobility, cough strength, muscle strength, physical activity, and quality of life-collected from Parkinson's patients via face-to-face interviews-will be analyzed. The data for all these assessments were collected in a single session lasting a maximum of approximately one hour. Step counts for each individual were tracked using a pedometer over a period of three days. | Other | Parkinson's disease group |
Primary outcome
Total quality of life score evaluated by Parkinson's Disease Questionnaire (PDQ-39) questionnaire.
Time frame: through study completion, an average of 1 year
The status of quality of life was evaluated using Parkinson's Disease Questionnaire (PDQ-39) questionnaire. Parkinson's Disease Questionnaire-39 (PDQ39) is a 39-item quality of life questionnaire. Evaluation for each question item ranges from 0 (no problem) to 4 (constant problem). Low scores in total indicate an improvement in people's quality of life.
5 secondary outcomes
Cough Strength
Time frame: through study completion, an average of 1 year
Daily average step count
Time frame: through study completion, an average of 1 year
Hand grip strength
Time frame: through study completion, an average of 1 year
Chest mobility
Time frame: through study completion, an average of 1 year
Cognitive status
Time frame: through study completion, an average of 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2026.
- Background: PubMed 32428342Shalash A, Roushdy T, Essam M, Fathy M, Dawood NL, Abushady EM, Elrassas H, Helmi A, Hamid E. Mental Health, Physical Activity, and Quality of Life in Parkinson's Disease During COVID-19 Pandemic. Mov Disord. 2020 Jul;35(7):1097-1099. doi: 10.1002/mds.28134. Epub 2020 Jun 7. No abstract available.
- Individual participant dataSharing planned: No
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
GÜLŞAH BARĞI, Assoc Prof study director
Izmir Democracy University
MERVE ŞAHİN principal investigator
Izmir Democracy University
ÖZLEM ÇİNAR ÖZDEMİR principal investigator
Abant Izzet Baysal University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson Disease, run by Izmir Democracy University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total quality of life score evaluated by Parkinson's Disease Questionnaire (PDQ-39) questionnaire. (time frame: through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07843667, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2026.